Publicaciones en colaboración con investigadores/as de University of Lubeck (51)

2024

  1. Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study

    Alzheimer's and Dementia, Vol. 20, Núm. 10, pp. 6722-6739

  2. Blood-based multivariate methylation risk score for cognitive impairment and dementia

    Alzheimer's and Dementia, Vol. 20, Núm. 10, pp. 6682-6698

  3. CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease

    Alzheimer's and Dementia, Vol. 20, Núm. 9, pp. 6205-6220

  4. Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: findings from mouse and human proteomic studies

    Fluids and Barriers of the CNS, Vol. 21, Núm. 1

  5. Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts

    npj Parkinson's Disease, Vol. 10, Núm. 1

  6. Paired plasma lipidomics and proteomics analysis in the conversion from mild cognitive impairment to Alzheimer's disease

    Computers in Biology and Medicine, Vol. 176

  7. Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson’s disease study

    Brain, Vol. 147, Núm. 8, pp. 2652-2667

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology

    Alzheimer's and Dementia, Vol. 19, Núm. 3, pp. 807-820

  3. Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort

    Movement Disorders, Vol. 38, Núm. 2, pp. 286-303

  4. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  5. Genotype–Phenotype Correlations for ATX-TBP (SCA17): MDSGene Systematic Review

    Movement Disorders, Vol. 38, Núm. 3, pp. 368-377

  6. Genotype–phenotype relations for episodic ataxia genes: MDSGene systematic review

    European Journal of Neurology, Vol. 30, Núm. 10, pp. 3377-3393

  7. Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN-derived networks and highlights causal links in Alzheimer's disease

    Alzheimer's and Dementia, Vol. 19, Núm. 8, pp. 3350-3364

  8. Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning

    Genome Medicine, Vol. 15, Núm. 1

  9. Whole-exome rare-variant analysis of Alzheimer's disease and related biomarker traits

    Alzheimer's and Dementia, Vol. 19, Núm. 6, pp. 2317-2331

2022

  1. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease

    Molecular neurodegeneration, Vol. 17, Núm. 1, pp. 27

  2. Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (Molecular Neurodegeneration, (2022), 17, 1, (27), 10.1186/s13024-022-00521-3)

    Molecular Neurodegeneration

  3. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

    Human Molecular Genetics, Vol. 31, Núm. 23, pp. 3945-3966

  4. Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 14, Núm. 1